| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/17/2002 | WO2001038878A3 Pin1 as a marker for abnormal cell growth |
| 01/17/2002 | WO2001037847A3 Nontoxic vernix compositions and method of producing |
| 01/17/2002 | WO2001036461A3 Compositions and methods for regulating tumor-associated antigen expression |
| 01/17/2002 | WO2001035948A3 Neurophilin ligands for treating ocular conditions |
| 01/17/2002 | WO2001035905A3 Personal care articles comprising cationic polymer coacervate compositions |
| 01/17/2002 | WO2001034833A3 Regulating endogenous inhibitor at atp synthase |
| 01/17/2002 | WO2001032706A3 Novel human transporter proteins and polynucleotides encoding the same |
| 01/17/2002 | WO2001032696A3 Traf family proteins |
| 01/17/2002 | WO2001030362A3 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 01/17/2002 | WO2001026603A3 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
| 01/17/2002 | WO2001022972A3 Immunostimulatory nucleic acids |
| 01/17/2002 | WO2001021259A3 Use and compositions for treating platelet-related disorders using anagrelide |
| 01/17/2002 | WO2001019407A3 Taxane prodrugs |
| 01/17/2002 | WO2001016377A3 Diagnostics and therapeutics for osteoporosis |
| 01/17/2002 | WO2001016293A3 Dna encoding the human serine protease t |
| 01/17/2002 | WO2001012598A3 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 01/17/2002 | WO2001012171A3 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases |
| 01/17/2002 | WO2001010468A3 Drug-carrier complexes and methods of use thereof |
| 01/17/2002 | WO2001007471A3 Cell cycle and proliferation proteins |
| 01/17/2002 | WO2001007087A3 Enzyme catalyzed anti-infective therapeutic agents |
| 01/17/2002 | WO2001001973A3 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/17/2002 | WO2000078971A3 Atp binding cassette transporter protein abc1 popypeptides |
| 01/17/2002 | WO2000078953A3 Human transport proteins |
| 01/17/2002 | WO2000078952A3 Human rna metabolism proteins (rmep) |
| 01/17/2002 | WO2000060077A3 Compounds for therapy and diagnosis of lung cancer and methods for their use |
| 01/17/2002 | WO1999051284A3 Non-covalent bioconjugates useful for diagnosis and therapy |
| 01/17/2002 | US20020007215 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007214 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007213 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/17/2002 | US20020007046 Polypeptides for use in the diagnosis, prevention and treatment of cancer and immunological defects |
| 01/17/2002 | US20020006964 Eating disorders; psychological disorders |
| 01/17/2002 | US20020006959 Therapy for reduced nervous cell metabolism |
| 01/17/2002 | US20020006951 Solid-state form of celecoxib having enhanced bioavailability |
| 01/17/2002 | US20020006950 Peroxidsome proliferator activated receptors |
| 01/17/2002 | US20020006941 p53 inhibitors and therapeutic use of the same |
| 01/17/2002 | US20020006926 Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| 01/17/2002 | US20020006921 Dopaminergic agent |
| 01/17/2002 | US20020006916 Promoters of neural regeneration |
| 01/17/2002 | US20020006913 Maintenance of Dna; reduce damage |
| 01/17/2002 | US20020006911 Administering mixture of jasmone, antioxidant and carnitine |
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| 01/17/2002 | US20020006898 Trimethyl lock based tetrapartate prodrugs |
| 01/17/2002 | US20020006445 Composition and method for treating the effects of diseases and maladies |
| 01/17/2002 | US20020006435 Local, topical transdermal anesthetic and vasodilator formulation of a topical anesthetic, topical vasodilator, and carrier; use prior to inserting an intravenous line into a patient |
| 01/17/2002 | US20020006418 Composition to enhance permeation of topical skin agents |
| 01/17/2002 | US20020006417 Heating the fill mass, cooling the fill mass, and encapsulating the fill mass into the capsule immediately after cooling; nutrients or drugs such as saquinavir |
| 01/17/2002 | US20020006410 Method for treating inflammatory diseases using heat shock proteins |
| 01/17/2002 | US20020006406 Lysostaphin an anti-staphylococcal agent for parenteral administration to mammals including humans exhibits the biological activity of proteolytic attack against glycincontaining bridges in the cell wall peptidoglycan of |
| 01/17/2002 | US20020006404 Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | US20020006383 Promoter of biosynthesis of skin cells |
| 01/17/2002 | US20020005206 Antiproliferative drug and delivery device |
| 01/17/2002 | DE10032132A1 Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung A dermal therapeutic system containing NSAIDs with selective COX-2 inhibition |
| 01/17/2002 | DE10030781A1 Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen Combination products of 3-N-Formylhydroxylaminopropylphosphonsäurederivaten or 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten special share with pharmaceutical agents |
| 01/17/2002 | CA2415967A1 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/17/2002 | CA2415919A1 Reagents and methods for identification of binding agents |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2415624A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | CA2415544A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/17/2002 | CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use |
| 01/17/2002 | CA2415179A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 01/17/2002 | CA2415127A1 Down syndrome critical region 1-like 1 proteins |
| 01/17/2002 | CA2415100A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | CA2415084A1 Olfactory neuron cultures and method of making and using the same |
| 01/17/2002 | CA2415052A1 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/17/2002 | CA2414938A1 Combinations of ssri and estrogenic agents |
| 01/17/2002 | CA2414510A1 Use of bioactive glass compositions to stimulate osteoblast production |
| 01/17/2002 | CA2414455A1 Pharmaceutical composition and method for the treatment of retroviral infections |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414219A1 Lipid metabolism molecules |
| 01/17/2002 | CA2414188A1 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | CA2414112A1 Treatment of male sexual dysfunction |
| 01/17/2002 | CA2414060A1 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | CA2413810A1 Aminoacyl trna synthetases |
| 01/17/2002 | CA2413044A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| 01/17/2002 | CA2412764A1 Stimulation of cellular regeneration and differentiation in the inner ear |
| 01/17/2002 | CA2412162A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | CA2412150A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | CA2412142A1 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/16/2002 | EP1172654A1 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors |
| 01/16/2002 | EP1172116A1 Pharmaceutical composition comprising anti-H.pylori urease IgY antibodies and an inhibitor of gastric acid secretion |
| 01/16/2002 | EP1172100A1 Oral solid pharmaceutical formulations with ph-dependent multiphasic release |
| 01/16/2002 | EP1172094A1 Composition, particularly for cosmetics, comprising DHEA and/or precursor or derivative, and at least a compound which increases the synthesis of glycosaminoglycans |
| 01/16/2002 | EP1172087A2 Topical treatment of skin |
| 01/16/2002 | EP1172084A2 Cosmetic and dermatologic composition to eliminate sebum |
| 01/16/2002 | EP1171629A1 Novel essential bacterial genes and their proteins |
| 01/16/2002 | EP1171614A1 Dsp-4 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171613A1 Dsp-7 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171599A1 Adipocyte complement related protein homolog zacrp2 |
| 01/16/2002 | EP1171595A1 13 transmembrane protein expressed in prostate cancer |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171580A2 Human homologues of fused gene |
| 01/16/2002 | EP1171579A1 Human tumor necrosis factor receptor tr9 |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171435A2 Pyrimidine-2-one derivatives as integrin receptor ligands |
| 01/16/2002 | EP1171165A1 Intramyocardial injection of autologous bone marrow |
| 01/16/2002 | EP1171163A1 Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders |
| 01/16/2002 | EP1171161A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 01/16/2002 | EP1171160A1 Method and means for treating post-polio syndrome |
| 01/16/2002 | EP1171157A2 Use of glucose-6-phospate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds |